EUVIMEDEUVIMED entdecken
Crossref

What clindamycin dose should be administered by continuous infusion during combination therapy with rifampicin? A prospective population pharmacokinetics study

Léo Mimram, Sophie Magréault, Younes Kerroumi, Dominique Salmon, Benjamin Kably, Simon Marmor, Anne-Sophie Jannot iD, Vincent Jullien, Valérie Zeller

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Léo Mimram und 8 weiteren Autor:innen. Beteiligte Einrichtung: Unité Fonctionelle de Pharmacologie, GHU Paris Seine Saint-Denis, Assistance Publique-Hôpitaux de Paris (APHP), Université Sorbonne Paris Nord, Bondy…. Hauptthemen laut MEDLINE: Clindamycin, Rifampin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite its important drug–drug interaction, combined clindamycin/rifampicin therapy may achieve effective plasma clindamycin concentrations, provided clindamycin is administered by continuous infusion. However, the precise clindamycin dose remains unknown.

Objectives

This study was undertaken to determine the daily clindamycin dose to be administered by continuous infusion in combination with rifampicin to achieve effective plasma clindamycin concentrations. Patients and methods Two plasma clindamycin concentrations were determined prospectively for 124 patients with bone-and-joint infections treated with continuously infused clindamycin. Twenty patients received clindamycin monotherapy, 19 clindamycin combined with rifampicin and 85 received clindamycin successively without and with rifampicin. A population pharmacokinetic model was developed using NONMEM 7.5. Monte Carlo simulations were run to determine which regimens obtained clindamycin concentrations of at least 3 mg/L.

Results

A linear one-compartment model with first-order elimination accurately described the data. Clindamycin distribution volume was not estimated. Mean clindamycin clearances with rifampicin and without, respectively, were 33.6 and 10.9 L/h, with 12.8% interindividual variability. The lowest daily clindamycin dose achieving plasma concentrations of at least 3 mg/L in >90% of the patients, when combined with rifampicin, was 4200 mg/24 h.

Conclusions

Our results support continuous infusion of 4200 mg of clindamycin/24 h, in combination with rifampicin. This high-dose regimen requires therapeutic drug monitoring-guided dose adaptation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClindamycinRifampinHumansProspective StudiesCombined Modality TherapyDrug Therapy, Combination

Substanzen

ClindamycinRifampin

Autor:innen und Institutionen

  • Unité Fonctionelle de Pharmacologie, GHU Paris Seine Saint-Denis, Assistance Publique-Hôpitaux de Paris (APHP), Université Sorbonne Paris Nord, Bondy, France.
  • IAME UMR 1137, Inserm and Sorbonne Paris Nord University, Team Biostatistic Modeling, Clinical Investigation and Pharmacometrics in Infectious Diseases, Paris, France.
  • Centre de Référence des Infections Ostéo-Articulaires Complexes (CRIOAc), Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, France.
  • Service de Médecine Interne, Hôpital Cochin, APHP, Paris, France.
  • Service de Pharmacologie DMU BioPhyGen, Hôpital Européen Georges-Pompidou, APHP, Paris, France.
  • Service d'Informatique Médicale, Biostatistiques et Santé Publique, Hôpital Européen Georges-Pompidou, APHP, Paris, France.

ORCID-Profile: Anne-Sophie Jannot

Zitieren

APA

Mimram, L., Magréault, S., Kerroumi, Y., Salmon, D., Kably, B., Marmor, S., Jannot, A. S., Jullien, V., & Zeller, V. (2023). What clindamycin dose should be administered by continuous infusion during combination therapy with rifampicin? A prospective population pharmacokinetics study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad335

Vancouver

Mimram L, Magréault S, Kerroumi Y, Salmon D, Kably B, Marmor S, et al. What clindamycin dose should be administered by continuous infusion during combination therapy with rifampicin? A prospective population pharmacokinetics study. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad335

BibTeX
@article{Mimram2023,
  author = {Mimram, Léo and Magréault, Sophie and Kerroumi, Younes and Salmon, Dominique and Kably, Benjamin and Marmor, Simon and Jannot, Anne-Sophie and Jullien, Vincent and Zeller, Valérie},
  title = {What clindamycin dose should be administered by continuous infusion during combination therapy with rifampicin? A prospective population pharmacokinetics study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad335}
}
Kostenlos starten →